These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

692 related items for PubMed ID: 25812601

  • 21. Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease.
    Zimran A, Wang N, Ogg C, Crombez E, Cohn GM, Elstein D.
    Am J Hematol; 2015 Jul; 90(7):577-83. PubMed ID: 25903392
    [Abstract] [Full Text] [Related]

  • 22. A Systematic Review and Meta-analyses of Longitudinal Studies on Drug Treatments for Gaucher Disease.
    Leonart LP, Fachi MM, Böger B, Silva MRD, Szpak R, Lombardi NF, Pedroso MLA, Pontarolo R.
    Ann Pharmacother; 2023 Mar; 57(3):267-282. PubMed ID: 35815393
    [Abstract] [Full Text] [Related]

  • 23. Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes.
    van Dussen L, Cox TM, Hendriks EJ, Morris E, Akkerman EM, Maas M, Groener JE, Aerts JM, Deegan PB, Hollak CE.
    Haematologica; 2012 Dec; 97(12):1850-4. PubMed ID: 22773601
    [Abstract] [Full Text] [Related]

  • 24. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
    Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, Zahrieh D, Crombez E, Bhirangi K, Barton NW, Zimran A.
    Am J Hematol; 2013 Mar; 88(3):166-71. PubMed ID: 23386328
    [Abstract] [Full Text] [Related]

  • 25. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM.
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [Abstract] [Full Text] [Related]

  • 26. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
    Serratrice C, Swiader L, Serratrice J.
    J Med Case Rep; 2015 Jun 23; 9():146. PubMed ID: 26100396
    [Abstract] [Full Text] [Related]

  • 27. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
    Amato D, Patterson MA.
    J Med Case Rep; 2018 Jan 27; 12(1):19. PubMed ID: 29373994
    [Abstract] [Full Text] [Related]

  • 28. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.
    Elstein D, Mellgard B, Dinh Q, Lan L, Qiu Y, Cozma C, Eichler S, Böttcher T, Zimran A.
    Mol Genet Metab; 2017 Sep 27; 122(1-2):113-120. PubMed ID: 28851512
    [Abstract] [Full Text] [Related]

  • 29. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology.
    Grabowski GA, Golembo M, Shaaltiel Y.
    Mol Genet Metab; 2014 May 27; 112(1):1-8. PubMed ID: 24630271
    [Abstract] [Full Text] [Related]

  • 30. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 27; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 31. Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan.
    Sagara R, Ishigaki M, Otsuka M, Murayama K, Ida H, Fernandez J.
    Orphanet J Rare Dis; 2021 Dec 04; 16(1):502. PubMed ID: 34863216
    [Abstract] [Full Text] [Related]

  • 32. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
    Elstein D, Dweck A, Attias D, Hadas-Halpern I, Zevin S, Altarescu G, Aerts JF, van Weely S, Zimran A.
    Blood; 2007 Oct 01; 110(7):2296-301. PubMed ID: 17609429
    [Abstract] [Full Text] [Related]

  • 33. [Therapeutic targets in Gaucher's disease].
    Giraldo P, Roca M.
    Med Clin (Barc); 2011 Sep 01; 137 Suppl 1():46-9. PubMed ID: 22230126
    [Abstract] [Full Text] [Related]

  • 34. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
    Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC.
    Lancet; 2015 Jun 13; 385(9985):2355-62. PubMed ID: 25819691
    [Abstract] [Full Text] [Related]

  • 35. Safety and efficacy of velaglucerase alfa replacement therapy for patients with type 1 Gaucher disease.
    Elstein D, Zimran A.
    Expert Rev Endocrinol Metab; 2013 Jul 13; 8(4):333-339. PubMed ID: 30736148
    [Abstract] [Full Text] [Related]

  • 36. Management of Gaucher disease: enzyme replacement therapy.
    Zimran A, Elstein D.
    Pediatr Endocrinol Rev; 2014 Sep 13; 12 Suppl 1():82-7. PubMed ID: 25345089
    [Abstract] [Full Text] [Related]

  • 37. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
    Cravo R, Rotman V, Oliveira PMN, Defendi HGT, Conceição DA, Xavier JR, Chertkoff R, Noronha TG, Maia MLS.
    Blood Cells Mol Dis; 2018 Feb 13; 68():160-162. PubMed ID: 28131618
    [Abstract] [Full Text] [Related]

  • 38. Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.
    Zimran A, Elstein D, Gonzalez DE, Lukina EA, Qin Y, Dinh Q, Turkia HB.
    Blood Cells Mol Dis; 2018 Feb 13; 68():153-159. PubMed ID: 27839979
    [Abstract] [Full Text] [Related]

  • 39. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience.
    Zimran A, Altarescu G, Philips M, Attias D, Jmoudiak M, Deeb M, Wang N, Bhirangi K, Cohn GM, Elstein D.
    Blood; 2010 Jun 10; 115(23):4651-6. PubMed ID: 20299511
    [Abstract] [Full Text] [Related]

  • 40. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.
    Pastores GM, Turkia HB, Gonzalez DE, Ida H, Tantawy AA, Qin Y, Qiu Y, Dinh Q, Zimran A.
    Blood Cells Mol Dis; 2016 Jul 10; 59():37-43. PubMed ID: 27282565
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.